PDK4 and lung cancer: In contrast, in lung cancer cells decreasing PDK4 expression both prevented the antiproliferative action of a PPARγ agonist by blocking its action at the G1 → S phase checkpoint (Srivastava et al. 2014) and promoted epithelial to mesenchymal transition and chemotherapy resistance.